June 29, 2020 / 11:58 AM / 3 days ago

BRIEF-Kiniksa Announces Positive Data From Phase 3 Trial Of Rilonacept In Recurrent Pericarditis (Rhapsody)

June 29 (Reuters) - Kiniksa Pharmaceuticals Ltd:

* KINIKSA ANNOUNCES POSITIVE DATA FROM PHASE 3 TRIAL OF RILONACEPT IN RECURRENT PERICARDITIS (RHAPSODY)

* KINIKSA PHARMACEUTICALS LTD - PRIMARY AND ALL MAJOR SECONDARY EFFICACY ENDPOINTS WERE HIGHLY STATISTICALLY SIGNIFICANT

* KINIKSA PHARMACEUTICALS LTD - PRIMARY AND ALL MAJOR SECONDARY EFFICACY ENDPOINTS WERE HIGHLY STATISTICALLY SIGNIFICANT

* KINIKSA PHARMACEUTICALS LTD - SAFETY RESULTS CONSISTENT WITH FDA-APPROVED LABEL FOR CAPS

* KINIKSA PHARMACEUTICALS LTD - SBLA SUBMISSION EXPECTED LATER THIS YEAR

* KINIKSA PHARMACEUTICALS LTD - RILONACEPT TREATMENT RESULTED IN A 96% REDUCTION IN RISK OF RECURRENT PERICARDITIS EVENTS

* KINIKSA PHARMACEUTICALS LTD - ADDITIONAL ANALYSES OF RHAPSODY TRIAL RESULTS ARE ONGOING Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below